HuMab 5B1 targeted amanitin conjugate - MabVax/WilexAlternative Names: HuMab 5B1-ADC; HuMab 5B1-ATAC
Latest Information Update: 11 Jan 2017
At a glance
- Originator Heidelberg Pharma; MabVax Therapeutics
- Class Immunoconjugates; Immunotoxins
- Mechanism of Action RNA polymerase II inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pancreatic cancer
Most Recent Events
- 06 Jan 2017 Preclinical trials in Pancreatic cancer in Germany (Parenteral) before January 2017
- 06 Jan 2017 Preclinical trials in Pancreatic cancer in USA (Parenteral) before January 2017